Literature DB >> 16459066

The role of stroma in immune recognition and destruction of well-established solid tumors.

Ping Yu1, Donald A Rowley, Yang-Xin Fu, Hans Schreiber.   

Abstract

Well-established solid tumors (at least 14 days old and >1cm in average diameter) are extremely difficult to eradicate immunologically in mice. Most cancer patients that seek medical attention bear primary or metastatic tumors that have grown for longer and that are larger than the tumors we call established. Therefore, focusing research on the problems of rejecting well-established mouse tumors might help in the development of novel concepts and protocols for destroying tumors in patients. A particular problem with established cancers is that even when treatments induce temporary regression, cancer often recurs. Recent studies suggest that manipulation of the stromal microenvironment of these tumors can induce immune recognition and regression. Furthermore, targeting cancer cells as well as tumor stroma for immune destruction might be needed to prevent recurrence.

Entities:  

Mesh:

Year:  2006        PMID: 16459066     DOI: 10.1016/j.coi.2006.01.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  43 in total

1.  New immune therapy targets tumor-associated environment: from bone marrow to tumor site.

Authors:  Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2011-12-12       Impact factor: 11.530

2.  Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Authors:  Alexander J Muller; James B DuHadaway; Mee Young Chang; Arivudinambi Ramalingam; Erika Sutanto-Ward; Janette Boulden; Alejandro P Soler; Laura Mandik-Nayak; Susan K Gilmour; George C Prendergast
Journal:  Cancer Immunol Immunother       Date:  2010-07-17       Impact factor: 6.968

3.  Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.

Authors:  Timothy P Moran; Joseph E Burgents; Brian Long; Ivana Ferrer; Elizabeth M Jaffee; Roland M Tisch; Robert E Johnston; Jonathan S Serody
Journal:  Vaccine       Date:  2007-07-17       Impact factor: 3.641

4.  Mechanism and therapeutic reversal of immune suppression in cancer.

Authors:  Donna L Herber; Srinivas Nagaraj; Julie Y Djeu; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

Review 5.  Use of tumour-responsive T cells as cancer treatment.

Authors:  Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

Review 6.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

7.  A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Authors:  Angela D Pardee; Dustin McCurry; Sean Alber; Peisheng Hu; Alan L Epstein; Walter J Storkus
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

8.  Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Authors:  James N Arnold; Lukasz Magiera; Matthew Kraman; Douglas T Fearon
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

Review 9.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

10.  B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer.

Authors:  Penghui Zhou; Xincheng Zheng; Huiming Zhang; Yang Liu; Pan Zheng
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.